Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Hardy-Werbin, Max
• dc.contributor.author Quiroga, Vanesa
• dc.contributor.author Cirauqui, Beatriz
• dc.contributor.author Romeo, Margarita
• dc.contributor.author Felip, Eudald
• dc.contributor.author Teruel, Iris
• dc.contributor.author García, Juan José
• dc.contributor.author Erasun, Carlos
• dc.contributor.author España, Sofia
• dc.contributor.author Cucurull, Marc
• dc.contributor.author Montprad, Elisabeth
• dc.contributor.author Pardo, Juan Carlos
• dc.contributor.author Carballo, Dania
• dc.contributor.author Velarde, José María
• dc.contributor.author Margeli, Mireia
• dc.date.accessioned 2020-04-17T06:57:03Z
• dc.date.available 2020-04-17T06:57:03Z
• dc.date.issued 2019
• dc.description.abstract T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed to taxanes and trastuzumab. We have performed a real-world study to complement the findings of the clinical trials. From 2012 to 2016, 15 patients with HER2-positive breast cancer who had progressed to prior treatment received T-DM1 at our center. We have retrospectively analyzed outcomes in these patients and compared our findings with those of the two clinical trials. Progression-free survival (PFS) was 10 months compared with the 9.6 months of the EMILIA trial and the 6.2 months of the TH3RESA trial, overall survival was 34 months compared with the 29.9 months of the EMILIA trial and the 22.7 months of the TH3RESA trial. PFS was ≥12 months in five patients, three of whom attained a PFS of ≥23 months. Among five patients with metastases of the central nervous system, PFS was six months, OS was not reached, and the objective response rate was 80%. Our findings are in line with those of the EMILIA study and slightly superior to those of the TH3RESA study. In our series of patients, T-DM1 has demonstrated efficacy in the treatment of HER2-positive metastatic breast cancer. Our real-world data thus confirm and support the findings of the two major phase III trials and indicate the usefulness of T-DM1 in routine clinical practice.
• dc.format.mimetype application/pdf
• dc.identifier.citation Hardy-Werbin M, Quiroga V, Cirauqui B, Romeo M, Felip E, Teruel I, et al. Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep. 2019 Sep 4; 9(1):12760. DOI: 10.1038/s41598-019-49251-5
• dc.identifier.doi http://dx.doi.org/10.1038/s41598-019-49251-5
• dc.identifier.issn 2045-2322
• dc.identifier.uri http://hdl.handle.net/10230/44253
• dc.language.iso eng
• dc.publisher Nature Research
• dc.rights © The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.other Mama -- Càncer -- Tractament
• dc.title Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion